
T-025
CAS No. ——
T-025( T025 | CLK inhibitor T-025 )
Catalog No. M16935 CAS No. ——
T-025 (T025, CLK inhibitor T-025) is an orally available, potent inhibitor of Cdc2-like kinases (CLKs) with Kd of 4.8, 0.096, 6.5, and 0.61 nM for CLK1, CLK2, CLK3, and CLK4, also inhibits DYRK1A and DYRK1B with IC50 of 0.074 and 1.5 nM.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
100MG | Get Quote | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameT-025
-
NoteResearch use only, not for human use.
-
Brief DescriptionT-025 (T025, CLK inhibitor T-025) is an orally available, potent inhibitor of Cdc2-like kinases (CLKs) with Kd of 4.8, 0.096, 6.5, and 0.61 nM for CLK1, CLK2, CLK3, and CLK4, also inhibits DYRK1A and DYRK1B with IC50 of 0.074 and 1.5 nM.
-
DescriptionT-025 (T025, CLK inhibitor T-025) is an orally available, potent inhibitor of Cdc2-like kinases (CLKs) with Kd of 4.8, 0.096, 6.5, and 0.61 nM for CLK1, CLK2, CLK3, and CLK4, also inhibits DYRK1A and DYRK1B with IC50 of 0.074 and 1.5 nM; reduces CLK-dependent phosphorylation, induces skipping exon, resulting in anti-proliferative effect in MDA-MB-468 in vitro and in vivo accompanied by the modulation of pre-mRNA splicing; shows sensitivity against high CLK2 expression or MYC amplification cancer celles; exhibits significant anti-tumor efficacy in MYC-driven breast tumor allograft models.
-
In Vitro——
-
In Vivo——
-
SynonymsT025 | CLK inhibitor T-025
-
PathwayCell Cycle/DNA Damage
-
TargetCLK
-
RecptorCLK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number——
-
Formula Weight382.431
-
Molecular FormulaC21H18N8
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameN2-methyl-N4-(pyrimidin-2-ylmethyl)-5-(quinolin-6-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Iwai K, et al. EMBO Mol Med. 2018 May 16. pii: e8289.
molnova catalog



related products
-
CLK inhibitor 2
A potent, selective inhibitor of cdc2-like kinase CLK1 and CLK2 with IC50 of 1.1 and 2.4 nM, respectively; moderately inhibits PI3Kα, and >100-fold selectivity over SRPK1/2/3.
-
ML167
A potent, selective CDC-like kinase 4 (CLK4) inhibitor with IC50 of 136 nM, >10-fold selectivity over Clk1, Clk2, Clk3, Dyrk1A/1B.
-
Leucettine L41
A novel potent cdc2-like kinase (CLKs) and DYRKs inhibitor with IC50 of 40, 35 and 15 nM for DYRK1A, DYRK2 and CLK1, respectively.